Screener / SEC EDGAR /CIK 0001759425 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Mirum Pharmaceuticals, Inc. MIRM

We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases. 10-K, Item 1

Headquarters
Foster City, CA
CEO
Christopher Peetz
Next results
around Jan 11, 2027
Compare with peers Embed

MIRM among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 54.7%, above 91% of 154 peers (their median 10.4%) REVENUE GROWTH 54.7% · above 91% Operating margin: -133.6%, above 6% of 138 peers (their median 10.2%) OPERATING MARGIN -133.6% · above 6% Net margin: -134.8%, above 5% of 153 peers (their median 6.8%) NET MARGIN -134.8% · above 5% FCF margin: -40.8%, above 10% of 144 peers (their median 10.1%) FCF MARGIN -40.8% · above 10%
MIRM Peer median Below the median

What changed

41 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 25, 2026 against Feb 26, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Inventory Costing (“As described in Notes 2 and 5 to the consolidated financial statements, inventory, which totaled $24.9 million as of December 31, 2025, is comprised of raw materials, work-in-progress and finished goods. Inventory is valued at the lower of cost or net realizable value, with cost determined on a firs”). No longer listed: Inventory. Same as last year: Table of Contents
  • Receivables +57.5% ($78.3M to $123.3M) vs revenue +54.7% ($336.9M to $521.3M), +2.8 pts apart
9 more checks with nothing to note
  • Cash from operations $55.8M vs net income −$23.4M (FY ending Dec 31, 2025)
  • Inventory +11.1% ($22.4M to $24.9M) vs revenue +54.7% ($336.9M to $521.3M), -43.7 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

41 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.

All 41 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    In clinical studies of brelovitug, the most common treatment-related AEs were injection-related events that resolved within 1-2 days, and cases of flu-like illness that were mild-moderate in severity.
  2. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    We participate in, or are subject to, the Medicaid Drug Rebate Program, as administered by Centers for Medicare & Medicaid Services (“CMS”), and other federal and state government pricing programs in the U.S., and we may participate, or be asked to participate, in additional government pricing programs or supplemental rebates in the…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    If generic manufacturers are successful in their use of litigation or regulatory means to obtain approval for generic versions of LIVMARLI, our revenue and results of operations would be adversely affected. The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Amendments of the Federal Food, Drug,…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    There have also been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act (“Affordable Care Act”) was enacted in the U.S., which substantially changed the way…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$77.1M$186.4M$336.9M$521.3M
Net income−$135.7M−$163.4M−$87.9M−$23.4M
Operating cash flow−$120.1M−$70.9M$10.3M$55.8M
Free cash flow−$120.4M−$71.1M$9.3M$54.9M

Revenue, FY2020 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$521.3M ▲ 54.7% in FY2025

FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

10 filings in the last 30 days · SEC EDGAR

All filings
5 more

About the company

Mirum Pharmaceuticals, Inc., Foster City, CA · from the 10-K filed Feb 25, 2026

We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We have three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), CHOLBAM® (cholic acid) capsules (“Cholbam”), and CTEXLI® (chenodiol) tablets (“Ctexli”).

Headquarters
Foster City, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 3, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIRM/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.